Compare AbbVie Inc (ABBV) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Hormel Foods Corp — how do they compare? AbbVie Inc trades at $250.09 (market cap $438.19B), while Hormel Foods Corp trades at $24.2 (market cap $13.59B). The key difference: AbbVie Inc is far larger — about 32.2× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| ABBV | HRL | |
|---|---|---|
Market Cap | $438.19B | $13.59B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $29.25 |
52-Week Low | $197.38 | $19.74 |
Enterprise Value | $502.45B | $15.59B |
Dividend Yield | 2.79% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Hormel Foods (HRL) trades at $25.02, down 0.32% on the day, with a neutral technical signal and bearish moving averages. The company shows mixed fundamentals with a P/E of 29.44 and net income margin of 3.82%, though it has beaten earnings estimates for three consecutive quarters. Recent developments include the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic focus.
Outlook remains cautious with analyst consensus at Hold and a $26.33 price target. Key opportunities include defensive dividend income and operational improvements, while risks involve margin pressure and consumer spending challenges. The stock offers steady income but faces growth headwinds in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
